2017 Session design of medical devices conference type 1 diabetes insulin dependent

Precise spatiotemporal control of drug delivery is essential in optimizing therapeutic effect and minimizing toxic side effects. Devices controlling the timing and location of delivery are of increasing importance for potent drugs. Conversely, local delivery of drugs can improve the efficiency of implanted devices by reducing infections and inflammation. This session features three presentations dealing with local delivery to improve performance of sensing and delivery catheters, feedback control of insulin delivery, and delivery of drugs by the vaginal route.

Ron Siegel received his ScD at MIT in 1984, and was a professor at the University of California at San Francisco from 1984-1998. He joined the University of Minnesota in 1998 and was Department Head of Pharmaceutics during 1999-2009.

He was President of the Controlled Release Society during 1997-1998. He has published widely in the areas of drug delivery, biosensing, pharmacokinetics and pharmacodynamics.

Mark E. Meyerhoff is Philip Elving Professor of Chemistry at the University of Michigan. He received his Ph.D. from SUNY-Buffalo in 1979. His research interests include the development of new electrochemical/optical sensors, and the design of polymeric materials/devices that can release/generate physiological levels of nitric oxide (NO) to prevent infection/clotting. He has authored 350 original research papers on these topics.

Lou Lintereur is a Distinguished Engineer and Technical Fellow at Medtronic Diabetes. He is the Lead Systems Integrator for the MiniMed 670G and has general responsibility for the engineering of Medtronic’s closed loop insulin delivery systems. Lou holds a B.S. in Aerospace Engineering from Purdue University and an M.S. in Aerospace Engineering from the Massachusetts Institute of Technology.

Matt Petersen received his Ph.D. from the University of Minnesota in Materials Science. He is currently a Principal Scientist at ProMed Pharma in Plymouth, Minnesota, where he leads technical development and scale-up of polymeric drug-device combination products, particularly for women’s health.

In this presentation, it will be shown that a variety of hydrophobic polymers often utilized to fabricate biomedical devices/systems can be formulated/designed with relatively simple chemistries to release or generate physiologically active levels of nitric oxide (NO) gas for days and weeks. It will be further shown that such NO release materials/devices can be employed to prepare intravascular or urinary catheters and other devices that exhibit potent antimicrobial and antithrombotic activities when tested in vitro and in vivo (in animals).

The MiniMed 670G system is a big step toward the ultimate goal of an artificial pancreas to treat Type 1 diabetes, and it is the world’s first system to offer closed loop control of basal insulin needs based on feedback from a continuous glucose monitor. This presentation will cover the fundamentals of closed loop insulin delivery systems, the basic technology roadmap for a fully automated artificial pancreas and an overview of the key challenges along the way.

Molded and extruded dosage forms have emerged as a versatile platform for delivery of a range of therapeutics in women’s health. This talk will address critical attributes and the current state of the art for these adaptable dosage form as well as address current areas of investigation and development. Challenges in formulating these sophisticated dosage forms will be discussed along with a brief discussion of relevant test methods.